Arctic Bioscience AS
Score · fiscal year 2025
26of 100
How to read this: the company is ahead of 13 % of companies in the Morning class Small in the same sector in 2025. What does this mean?
Rank in the Morning class Small: 1,389 of 1,600 · What are Morning company classes?
Place in the whole sector: 3,770 of 4,312 · Industri
Profile
Elephant · Steward
Lower profitability, high solidity
Position against comparable companies in 2025, not a verdict on the company. Based on profitability 7 and solidity 77 out of 100 among companies in the Morning class Small in the same sector in 2025. Methodology
Against the sector
Arctic Bioscience AS is 25 points below the median for companies in the Morning class Small in the same sector in 2025.
Median score 51 among 1,600 companies.
Against companies in the Morning class Small in the same sector in 2025: operating margin −73.4% (median 4.4%) and equity ratio 61.6% (median 41.2%).
The numbers behind the score
| Measure | Company | Median |
|---|---|---|
| Operating revenue | 41 MNOK | 23 MNOK |
| Operating margin | −73.4% | 4.4% |
| Profit margin | −104.6% | 4.2% |
| Return on assets | −9.5% | 9.5% |
| Equity ratio | 61.6% | 41.2% |
| Debt-to-equity | 0.62 | 1.30 |
| Current ratio | 0.65 | 1.72 |
| Revenue growth | −6.3% | 5.4% |
| Revenue per employee | 2.91 MNOK | 1.65 MNOK |
The median and “ahead of” refer to companies in the Morning class Small in the same sector in 2025. The bar shows the share of companies the figure is ahead of.
With an index of 26, Arctic Bioscience AS does better than 13% of companies in the Morning class Small in the same sector (1,600 companies) in 2025.
Score 2023–2025
- Arctic Bioscience AS
- Median: companies in the Morning class Small in the same sector
Arctic Bioscience AS has a score of 26 for 2025, rank 3,770 of 4,312 in the sector.
Strongest: Solidity: percentile 77 against peers, equity ratio 61.6% against a median of 41.2%.
Weakest: Liquidity: percentile 4 against peers, current ratio 0.65 against a median of 1.72. Consistency: percentile 5 against peers.
Worth a closer look
- Consider strengthening liquidity: current liabilities are 1.5 times current assets. Based on: current ratio 0.65 (median 1.72).
- The company made a loss before tax. Are these one-off items or a pattern? Based on: profit margin −104.6% (median 4.2%).
- The operating margin is lower than at three in four companies in the sector. Where do costs differ from competitors? Based on: operating margin −73.4% (median 4.4%).
- What lies behind weak consistency, and will it last?
Written by fixed rules from the figures. Describes the figures, does not explain causes. Not investment or financial advice. How the summary is made
The industry or the company: what drove the result?
In 2025 the operating margin of Arctic Bioscience AS rose by 25.3 percentage points. Comparable companies rose by a median 0.1 points. So the company did 25.2 points better than the industry, for reasons of its own.
Over 2 year-to-year changes Arctic Bioscience AS moved the same way as comparable companies 0 times. About 1% of the changes in operating margin were common to the industry; the rest was the company's own.
| Year | The company | Comparable (median) | Change, company | Change, industry | The company's own |
|---|---|---|---|---|---|
| 2024 | −98.7% | 4.3% | +34.2 percentage points | −0.2 percentage points | +34.4 percentage points |
| 2025 | −73.4% | 4.4% | +25.3 percentage points | +0.1 percentage points | +25.2 percentage points |
Comparable companies are those in the same industry and Morning company class. Their change shows what hit the whole industry, the sector drivers below included. The rest is the company's own: contracts, costs, one-off items or operations. The share is approximate, and we claim no cause.
The company and its sector's drivers
Prices, rate and currency that shape the sector's year, year by year beside the operating margin of Arctic Bioscience AS. The figures stand side by side; we claim no cause.
Producer prices in manufacturing (indeks (2021 = 100))
Producer prices in manufacturing rose 2.9% in 2025; the operating margin of Arctic Bioscience AS rose 25.3 percentage points.
| Measure | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Producer prices in manufacturing, annual average | 100.0 | 124.7 | 129.5 | 134.4 | 138.3 | 146.0 (so far) |
| Change from the year before | +10.7% | +24.7% | +3.9% | +3.7% | +2.9% | +5.6% |
| The company's operating margin | – | – | −132.9% | −98.7% | −73.4% | – |
Source: SSB (12462, CC BY 4.0). Source
EUR/NOK (kr)
EUR/NOK rose 0.8% in 2025; the operating margin of Arctic Bioscience AS rose 25.3 percentage points.
| Measure | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| EUR/NOK, annual average | 10.16 | 10.10 | 11.42 | 11.62 | 11.72 | 11.04 (so far) |
| Change from the year before | −5.2% | −0.6% | +13.1% | +1.8% | +0.8% | −5.8% |
| The company's operating margin | – | – | −132.9% | −98.7% | −73.4% | – |
Source: Norges Bank (EXR, NLOD 2.0). Source
Wholesale power price (øre per kWh)
Wholesale power price rose 9.4% in 2025; the operating margin of Arctic Bioscience AS rose 25.3 percentage points.
| Measure | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Wholesale power price, annual average | 64.2 | 141.7 | 72.0 | 49.4 | 54.0 | 96.5 (so far) |
| Change from the year before | +466.7% | +120.8% | −49.2% | −31.4% | +9.4% | +78.4% |
| The company's operating margin | – | – | −132.9% | −98.7% | −73.4% | – |
Source: SSB (09363, CC BY 4.0). Source
USD/NOK (kr)
USD/NOK fell 3.3% in 2025; the operating margin of Arctic Bioscience AS rose 25.3 percentage points.
| Measure | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| USD/NOK, annual average | 8.59 | 9.61 | 10.56 | 10.75 | 10.39 | 9.54 (so far) |
| Change from the year before | −8.8% | +11.9% | +9.9% | +1.7% | −3.3% | −8.2% |
| The company's operating margin | – | – | −132.9% | −98.7% | −73.4% | – |
Source: Norges Bank (EXR, NLOD 2.0). Source
Wage index: fabricated metal products (indeks)
Wage index: fabricated metal products rose 5.8% in 2025; the operating margin of Arctic Bioscience AS rose 25.3 percentage points.
| Measure | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Wage index: fabricated metal products, annual average | 88.0 | 91.5 | 96.9 | 102.1 | 108.0 | 112.8 (so far) |
| Change from the year before | +3.1% | +3.9% | +6.0% | +5.4% | +5.8% | +4.5% |
| The company's operating margin | – | – | −132.9% | −98.7% | −73.4% | – |
Source: SSB (12314, CC BY 4.0). Source
We show the drivers and the margin side by side and claim no cause. Sensitivity per company is not computed until we have at least 10 years of accounts per company: with three years such figures are false precision.
What the numbers say
Arctic Bioscience AS had an operating margin of −73.4% and an equity ratio of 61.6% in 2025, and ranks 3,770 of 4,312 in Industri.
From 2024 to 2025: the operating margin rose from −98.7% to −73.4% and the equity ratio fell from 76.2% to 61.6%.
This text is generated automatically from the 2025 accounts.
Three simple methods
One method gives a figure: 320 MNOK.
| Method | Multiple | Estimate |
|---|---|---|
| P/E | 22.2 | not meaningful |
| EV/EBIT | 18.6 | not meaningful |
| P/B | 3.0 | 320 MNOK |
The listed basis is the value at listed multiples. The estimate is lowered by 39% for an unlisted company: 20% for lack of marketability and 24% for size (a small-company premium of 2% on the cost of equity).
A mechanical estimate from public accounts, not advice. A mechanical estimate from public accounts with listed multiples and fixed adjustments. Not a valuation and not advice to buy or sell. See the calculation
Worth a closer look
- watch
Consider strengthening liquidity: current liabilities are 1.5 times current assets.
Based on: Current ratio 0.65 (median 1.72).
- watch
The company made a loss before tax. Are these one-off items or a pattern?
Based on: Profit margin −104.6% (median 4.2%).
- watch
The operating margin is lower than at three in four companies in the sector. Where do costs differ from competitors?
Based on: Operating margin −73.4% (median 4.4%).
Indications based on the latest annual accounts from open data. Not investment or financial advice.
Financial costs were 14.4% of the debt in 2025. The policy rate averaged 4.30 % the same year. This is a plain description of what the debt cost, not a model of interest sensitivity.
See interest rates, prices and exchange rates for the sector
Data quality
No anomalies found in the figures.
Scenario analysis: the sector's weakest year
We have no accounts for 2022, the sector's weakest year, for this company.
The sector's weakest year was 2022, with a median operating margin of 0.4%. Based on the 10 fiscal years we have. The analysis grows as more years are fetched or imported. Methodology
What the score is made of
| Profitability | 7 | weight 30% |
|---|---|---|
| Solidity | 77 | weight 25% |
| Liquidity | 4 | weight 15% |
| Growth | 24 | weight 15% |
| Consistency | 5 | weight 15% |
Durability: 41 (average over 3 years)
Index version 2. Data completeness 100%: the share of the weights that had data.
Questions and answers
How profitable is Arctic Bioscience AS?
The operating margin was −73.4% in 2025, against a median of 4.4% among companies in the Morning class Small in the same sector. Return on assets was −9.5%. The company made a loss before tax.
How solid is Arctic Bioscience AS?
The equity ratio was 61.6% in 2025 (median 41.2%). Debt-to-equity was 0.62 (median 1.30).
What is the liquidity of Arctic Bioscience AS like?
The current ratio was 0.65 in 2025 (median 1.72). Current assets did not cover current liabilities.
How does Arctic Bioscience AS compare in Industri?
Arctic Bioscience AS ranks 3,770 of 4,312 in Industri for 2025. Among companies in the Morning class Small it is number 1,389 of 1,600. Revenue changed by −6.3% from the year before.
Group accounts · 2025
25 of 100
Rank 156 of 175 groups in Industri. Groups are ranked only against other groups in the same sector, never against single companies.
- Operating revenue, group
- 43 MNOK
- Operating profit, group
- −33 MNOK
- Profit before tax, group
- −41 MNOK
- Total assets, group
- 285 MNOK
- Equity, group
- 173 MNOK
| Key figure | The group | The company alone (2025) |
|---|---|---|
| Operating margin | −78.5% | −73.4% |
| Return on assets | −10.8% | −9.5% |
| Equity ratio | 60.9% | 61.6% |
| Current ratio | 0.59 | 0.65 |
| Revenue growth | −4.0% | −6.3% |
Group index in earlier years: 2023: 56 (81 of 200), 2024: 39 (127 of 178).
Same formulas and weights as the company index. Group and company are never added together, and the group accounts are not part of sector averages or company rankings.
Source: Brønnøysund Register Centre, group accounts 2025 (open data, NLOD 2.0).
Group structure · 2025
5 companies in the group according to the shareholder register for 2025. A company counts as a subsidiary when a Norwegian company owns more than half of its shares.
No owner holds more than half of the shares in Arctic Bioscience AS.
Group accounts. Arctic Bioscience AS for 2025: index 25 of 100, number 156 of 175 groups.
-
Arctic Bioscience AS you are here
Read the figures with care: a company in a group can look strong because of group contributions, or weak because dividends go up to the parent. The figures are indications, not the full picture.
Source: the Norwegian Tax Administration's shareholder register 2025 (majority owner with more than 50 % of the shares). Voting agreements and ownership through other countries are not included.
From the Central Coordinating Register
- Org. no.
- 996638812
- Legal form
- AS
- Sector
- Industri (10.410)
- Morning company class
- Small
- Employees
- 14 registered 10 October 2026
- Founded
- 15 February 2011 15 years in operation
- Share capital
- 2.70 MNOK
- Business address
- Industrivegen 42, 6155 ØRSTA
- Municipality
- Ørsta rank 14–35 of 38 in KOSTRA group 7
- Latest accounts filed
- 2025
- LEI
- 549300Z2HW6I989Q2C78 renews 24 April 2027
Source: Central Coordinating Register, Brønnøysund Register Centre. The employee count is reported by the company and may be older than the accounts. See the company at the Brønnøysund Register Centre
Ownership and roles
Loading roles …
Source: Central Coordinating Register, fetched 1 November 2026. Only names are shown.
- Parent company
- No parent company: owned by persons
Source: GLEIF (Global Legal Entity Identifier Foundation), fetched 30 October 2026. The parent is the one the company itself reported to GLEIF.
Shareholders (2025)
- Number of shareholders
- 1,021
- Largest owner
- 11.5% · top three 22.1%
- Split
- companies 80% · private persons 20% · foreign 10%
- Owned from the same municipality
- 15%
- Owners over 60
- 42% of the shares held by persons (median age 57)
- Ronja Capital Investment AS · 11.5%
- Capra Invest AS · 5.7%
- Mrfk Holding AS · 4.9%
- J.P. Morgan SE (Luxembourg) · 4.2%
- Vartdal Holding AS · 3.9%
- Brødrene Vartdal AS · 3.0%
- Kotler Equity Investment LIMITED (China) · 2.5%
- Hawk Infinity AS · 2.2%
- Stette Invest AS · 2.2%
- Kjølås Stansekniver AS · 2.1%
- 837 private persons · 19.6%
The company is new in the shareholder register in 2025.
Majority owner of: Arctic Biopharma AS (100%), Arctic Nutrition AS (100%), Romega AS (100%), Arctic Algae AS (100%)
Holds shares in: Arctic Algae AS (100%), Arctic Biopharma AS (100%), Romega AS (100%), Arctic Nutrition AS (100%)
The owners' shares do not add up to the company's total number of shares in the source.
Source: the Norwegian Tax Administration's shareholder register as of 2025. Figures may be older than today's ownership. Private persons are not shown by name.
Error in the data?
Do you see an error in the figures or in how the company is mapped (sector, holding, group)? Let us know. Corrections require documentation.
Figures last fetched 5 November 2026.
Year by year · 2023–2025
| Key figure | 2023 | 2024 | 2025 | Trend |
|---|---|---|---|---|
| Index | 56 | 40 | 26 | |
| Rank | 1,639 | 2,965 | 3,770 | |
| Operating margin | −132.9% | −98.7% | −73.4% | |
| Return on assets | −13.1% | −14.0% | −9.5% | |
| Equity ratio | 87.2% | 76.2% | 61.6% | |
| Current ratio | 3.38 | 0.89 | 0.65 | |
| Revenue growth | – | 28.8% | −6.3% |
Accounts
From the Brønnøysund Register Centre, in the company's reporting currency (NOK).
| Key figure | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating revenue | 33.8 MNOK | 43.5 MNOK | 40.8 MNOK |
| Operating profit | −44.9 MNOK | −42.9 MNOK | −29.9 MNOK |
| Profit before tax | −41.3 MNOK | −49.1 MNOK | −42.6 MNOK |
| Tax expense | 0.0 MNOK | 0.0 MNOK | 0.0 MNOK |
| Net profit | −41.3 MNOK | −49.1 MNOK | −42.6 MNOK |
| Financial expenses | 1.9 MNOK | 9.9 MNOK | 15.8 MNOK |
| Total assets | 301.4 MNOK | 280.5 MNOK | 284.1 MNOK |
| Current assets | 130.3 MNOK | 59.3 MNOK | 53.3 MNOK |
| Equity | 262.8 MNOK | 213.8 MNOK | 175.0 MNOK |
| Retained earnings | – | – | – |
| Total liabilities | 38.6 MNOK | 66.7 MNOK | 109.1 MNOK |
| Current liabilities | 38.6 MNOK | 66.7 MNOK | 81.8 MNOK |
Source: Brønnøysund Register Centre (Register of Company Accounts), fetched 5 November 2026, accounts id 6798166.
Further
Similar companies
- Aqua Innovasjon AS index 26, rank 3,758 · compare
- Elmento AS index 26, rank 3,759 · compare
- Pro Pack Container AS index 26, rank 3,767 · compare
- Troll Systems AS index 26, rank 3,776 · compare
- Snåsavann AS index 26, rank 3,777 · compare